Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30363546 | 0.97 | PKM (0.37) | PKM | |
| SCHEMBL218350 | 0.86 | ALDH1A1 (0.40) | PKMTDP1ALDH1A1HTTNPSR1 | |
| SCHEMBL9951769 | 0.79 | ALDH1A1 (0.36) | PKMALDH1A1HTTNPSR1 | |
| SCHEMBL20910305 | 0.78 | PKM (0.48) | PKMTDP1ALDH1A1 | |
| SCHEMBL587339 | 0.74 | FFAR3 (0.35) | PKMTDP1ALDH1A1HTTNPSR1 | |
| SCHEMBL15514232 | 0.74 | ALDH1A1 (0.31) | ALDH1A1HTTNPSR1 | |
| SCHEMBL22941948 | 0.74 | PKM (0.32) | PKM | |
| SCHEMBL25041122 | 0.73 | ALDH1A1 (0.33) | ALDH1A1HTT | |
| SCHEMBL20721222 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HTTNPSR1 | |
| SCHEMBL7723088 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | claimed |
| CN-115667259-B | Fused ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2025-06-17 | — | — | CN | claimed |
| EP-4423075-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | claimed |
| CN-118401522-A | Azaindole derivatives inhibiting H-PGDS | 佐藤制药株式会社 | 2024-07-26 | — | — | CN | claimed |
| EP-4175949-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | claimed |
| WO-2023073082-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | WO | claimed |
| CN-115989223-A | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | claimed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-115667259-B | Fused ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2025-06-17 | — | — | CN | disclosed |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| WO-2025024726-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-118666869-A | Bridged ring compounds, pharmaceutical composition and application thereof | 上海湃隆生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-1581515-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2005-07-14 | — | — | US | disclosed |
| US-6849636-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004058730-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058741-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | PKM 4151/4885TDP1 2116/4885ALDH1A1 346/4885 |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | PKM 2796/4885TDP1 4241/4885ALDH1A1 780/4885 |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | PKM 1889/4885TDP1 691/4885ALDH1A1 145/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | PKM 2514/4885TDP1 3038/4885ALDH1A1 586/4885 |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | PKM 1910/4885TDP1 684/4885ALDH1A1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.